Genetically Engineered Virus Kills Liver Cancer
Scientists reported that a genetically engineered virus tested in 30 terminally-ill liver cancer patients significantly prolonged their lives, killing tumors and inhibiting growth of new ones. The vaccine Pexa-Vec, or JX-594 has been engineered from the vaccinia virus, which has been used as vaccine for decades.
The report in the journal Nature Medicine said that 16 patients who received high dose of the therapy survived for 14.1 months on average, while the rest who were given a low dose survived for 6.7 months. Pexa-Vec treatment at both doses showed reduction of tumor size and decreased blood flow to tumors.
Read the news release at http://medicalxpress.com/news/2013-02-genetically-virus-cancer.html. The abstract and author information is available at Nature Medicine: http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.3089.html#/abstract.
This article is part of the Crop Biotech Update, a weekly summary of world developments in agri-biotech for developing countries, produced by the Global Knowledge Center on Crop Biotechnology, International Service for the Aquisition of Agri-Biotech Applications SEAsiaCenter (ISAAA)